IRIDEX Announces Receipt of Large Orders for Laser Systems from Developing Countries

  IRIDEX Announces Receipt of Large Orders for Laser Systems from Developing

Orders from BRIC Countries Demonstrate Cost, Durable Therapeutic Advantages of
Laser-Based Treatments for Ophthalmologic Diseases

PR Newswire

MOUNTAIN VIEW Calif., April 30, 2013

MOUNTAIN VIEW Calif., April 30, 2013 /PRNewswire/ -- IRIDEX Corporation
(Nasdaq:IRIX) today announced that it has recently received two significant
orders for its proprietary laser-based medical systems for the treatment of
eye diseases. The orders, totaling more than $500,000, are indicative of the
burgeoning growth of the ophthalmology market in the "BRIC" economies (Brazil,
Russia, India and China) as well as the advantages of modern laser treatments,
noted Will Moore, President and CEO of IRIDEX.

"We believe that the growth in the market for lasers is being driven in large
part by the rapid spread of diabetes and diabetes-related eye diseases in
developing countries as well as the practicality of new laser treatments,"
Moore added.

"Diabetes is reaching epidemic proportions in many developing parts of the
world, and with that comes the spread of diabetes-related eye diseases such as
Diabetic Macular Edema, or DME," Moore said. "The health systems in many
countries, because of logistics and cost, do not support the current drug
treatment model for these diseases we see here in the US, which typically
includes a regular series of drug injections in the eye. These ongoing
injections are neither practical in remote areas, nor are they cost-effective.
Our laser-based medical systems are as effective as drugs in terms of
outcomes, are much less costly to a healthcare system, and are much easier to
administer from a logistics standpoint because they provide durable results."

Moore added that the advances in laser-based therapies are causing the
beginnings of a paradigm shift in the U.S. and European ophthalmology markets,
as well.

"We believe the treatment pendulum, which shifted from lasers to drugs for
diseases like DME several years ago, is beginning to shift back to lasers
thanks to the new advances in modern laser technology," Moore said.


IRIDEX Corporation was founded in 1989 and is a worldwide leader in
developing, manufacturing, and marketing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation for the
ophthalmology market. We maintain a deep commitment to the success of our
customers, with comprehensive technical, clinical, and service support
programs. IRIDEX is dedicated to a standard of excellence, offering superior
technology for superior results. IRIDEX products are sold in the United States
through a direct sales force and internationally through a combination of a
direct sales force and a network of approximately 70 independent distributors
into over 100 countries. For further information, visit the IRIDEX website at

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Act of 1934, as amended, relating to the markets for the Company's
products, the growth of ophthalmology markets in developing countries, the
prevalence of diabetes and diabetes-related eye diseases in developing
countries, the effectiveness of the Company's products and the Company's
belief regarding emerging trends in the standards of treatment for
diabetes-related eye diseases. These statements are not guarantees of future
performance and actual results may differ materially from those described in
these forward-looking statements as a result of a number of factors. Please
see a detailed description of these and other risks contained in our Annual
Report on Form 10-K for the fiscal year ended December29, 2012, filed with
the Securities and Exchange Commission. Forward-looking statements contained
in this announcement are made as of this date and will not be updated.


Contact: IRIDEX, Jim Mackaness, CFO & COO, +1-650-940-4700 or Investor
Relations, Matt Clawson, Allen & Caron, +1-949-474-4300
Press spacebar to pause and continue. Press esc to stop.